GlassScriptPhysician profile
Serge Lartchenko
NPI 1992787089
$7,456.31
in general payments reported to CMS, 2019-2025
29 companies · $952 in 2025
The $952 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,466 · 2021: $902 · 2022: $914 · 2023: $728 · 2024: $817 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $28.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.78 |
| Education | $28.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,518.66 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,288.55 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,231.00 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Gilead Sciences, INC. | $827.32 | 2019-2025 | Biktarvy |
| Insmed, INC. | $431.51 | 2019-2025 | Arikayce |
| Theratechnologies INC. | $406.88 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Products, LP | $318.94 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $243.57 | 2019-2025 | Vibativ |
| Mayne Pharma Commercial LLC | $176.53 | 2019-2020 | |
| Kerecis Limited | $120.86 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Ferring Pharmaceuticals INC. | $117.84 | 2023-2025 | Rebyota |
| Cipla USA INC. | $102.93 | 2021 | |
| Melinta Therapeutics, LLC | $93.85 | 2019-2020 | |
| Smith+Nephew, INC. | $76.14 | 2022-2024 | Oasis, Grafix Pl, Renasys Touch |
| Paratek Pharmaceuticals, INC. | $72.96 | 2020-2025 | Nuzyra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.28 | 2019-2020 | |
| Emd Serono, INC. | $51.92 | 2019-2023 | Serostim |
| Acera Surgical, INC. | $49.26 | 2024-2025 | Restrata Wound Matrix |
| Shionogi INC | $40.85 | 2020 | |
| Shire North American Group INC | $32.79 | 2019 | |
| Aimmune Therapeutics, INC. | $31.54 | 2025 | Zenpep |
| Tetraphase Pharmaceuticals, INC. | $31.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Abbvie INC. | $23.64 | 2023 | |
| Romark Laboratories, Lc | $22.59 | 2019 | |
| Polynovo North America LLC | $16.55 | 2024 | Novosorb Btm |
| Tactile Systems Technology INC | $14.53 | 2019 | |
| Nabriva Therapeutics, Plc | $11.63 | 2020 | |
| Janssen Scientific Affairs, LLC | $9.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Lartchenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.